Nessan Bermingham is an Operating Partner at Khosla Ventures. He focuses on Life Science companies with a particular emphasis on nucleic acid editing, novel delivery systems, gene & cell therapy, novel target identification and data analytics for drug discovery and development.
Nessan is a serial biotech entrepreneur and investor having founded multiple companies in the Life Sciences space, most notably Intellia Therapeutics “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company”, Triplet Therapeutics and Korro Bio. At Intellia, Nessan led the company from concept through partnering deals, multiple financings and an IPO prior to its second anniversary. He served as president and CEO from inception until December 2017. Intellia’s work has led the field of genome engineering showing the first in vivo systemic delivery of CRISPR Cas9 for the potential curative treatment of ATTR, an inherited genetic disorder.
Nessan has held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He is currently Chair of F-star, Executive Chair of Korro Bio and Triplet Therapeutics.
Previously he was a member of the equity research team at UBS, an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.
In his spare time Nessan is an avid mountain downhill biker, snowboarder and ultra-trail runner.